TNFSF13 Protein (AA 105-250, N-Term)

Catalog No. ABIN2667376

Product Details

Target: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Protein Type: Recombinant

Protein Characteristics: AA 105-250, N-Term

Origin: Human

Source: Escherichia coli (E. coli)

Application: ELISA, Multiplex Assay (MA)

Purity: Purity is >90 % as determined by SDS-PAGE under reducing conditions, stained with silver stain.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.,Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Prior to use, reconstitute the lyophilized powder with 0.2 mLof PBS containing a carrier protein (e.g., 1 % BSA, protease free), pH 7.4. Re-cap vial, vortex. Allow the reconstituted standard to sit at room temperature for 15 minutes, vortex again to mix completely. The reconstituted standard stock solution can be aliquoted into polypropylene vials and stored at -70 °C for up to one month.

Buffer: Lyophilized in sterile-filtered PBS, pH 7.2, containing 1 % BSA.

Handling Advice: Use a manual defrost freezer and avoid repeated freeze thaw cycles.

Storage: 4 °C

Storage Comment: Upon receipt, store unopened vials between 2°C and 8°C immediately and use within 12 months from date of receipt.

Expiry Date: 12 months

Target Details

Target: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Alternative Name: APRIL (TNFSF13 Products)

Background: APRIL (A Proliferation-Inducing Ligand), also known as TNFSF13, stimulates cell proliferation. It is a member of the TNF superfamily of ligands, being most closely related to BAFF, with which it shares 30 % amino acid sequence identity. APRIL is cleaved intracellularly by furin and is believed to exist mainly in a secreted, soluble form. As with most other TNF family members, APRIL exists as a functional homotrimer (total MW = 90 kD). It can bind to two cell-surface receptors: BCMA and TACI, which it shares with BAFF, to exert downstream T- and B-cell regulatory effects. It also possesses a heparin binding domain and has been demonstrated to bind to proteoglycans on the cell surface. APRIL is most well known for its tumor proliferation effects. It is a potential biomarker, with serum levels elevated for certain cancers and expression levels elevated in cancer tissues. It is also a potential biomarker for certain autoimmune diseases. In fact, recombinant TACI has been brought to clinical trials as a neutralization drug against APRIL and BAFF for the treatment of systemic lupus erythematosus (SLE). Besides forming homotrimers, APRIL can also form functional heterotrimers with BAFF. The stoichiometric relationship of the protomeric units is still unclear, however, it appears that these heterotrimers are significant in that they are elevated in the serum of certain autoimmune patients. APRIL also forms an endogenous chimeric protein with another related protein, TWEAK, effectively called TWE-PRIL. It is believed that TWE-PRIL is membrane bound, and consists of the N-terminus of TWEAK with its transmembrane domain, and the C-terminus of APRIL with its receptor binding domain.

Molecular Weight: The recombinant protein has a predicted molecular weight of 21.7 kDa. The DTT-reduced protein migrates at approximately 26 kDa by SDS-PAGE.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response